Improving baroreceptor activation therapy to reduce side effects
A Rational Engineering Design Approach to Minimizing the Off-Target Effects of Baroreceptor Activation Therapy
This study is looking at ways to make a treatment called baroreceptor activation therapy (BAT) better for people with high blood pressure and heart failure by reducing any side effects, so that it can help those who haven't found relief with regular treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Wisconsin-Madison NIH-funded |
| Lab location | 1 site (Madison, United States) |
| Project ID | NIH-11055382 on NIH RePORTER |
What this research studies
This research investigates how to enhance baroreceptor activation therapy (BAT), a treatment for hypertension and heart failure, by minimizing its side effects. The team will explore the neuroanatomy involved in these side effects and develop optimized neural interfaces for BAT. By using advanced engineering techniques, they aim to create a more effective therapy that can provide better outcomes for patients who do not respond to traditional treatments. The project seeks to translate these findings into clinical applications that can directly benefit patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults suffering from resistant hypertension or heart failure who have not responded well to standard medical therapies.
Not a fit: Patients with mild hypertension or heart failure who are effectively managed with current medications may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a more effective treatment for hypertension and heart failure with fewer side effects.
How similar studies have performed: Previous studies have shown that baroreflex activation therapy can improve outcomes for patients with hypertension and heart failure, but this approach to optimizing the therapy is novel.
Where this research is happening
Madison, United States
- University of Wisconsin-Madison — Madison, United States (Active)
Researchers
- Principal investigator: Ludwig, Kip a — University of Wisconsin-Madison
- Study coordinator: Ludwig, Kip a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.